Compare UPLD & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPLD | JSPR |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 14.9M |
| IPO Year | 2014 | N/A |
| Metric | UPLD | JSPR |
|---|---|---|
| Price | $5.02 | $0.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $3.75 | ★ $15.50 |
| AVG Volume (30 Days) | 62.7K | ★ 597.2K |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.38 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,767,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.95 | N/A |
| 52 Week Low | $0.50 | $0.32 |
| 52 Week High | $6.65 | $3.52 |
| Indicator | UPLD | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 70.06 | 65.26 |
| Support Level | $0.62 | $0.62 |
| Resistance Level | $5.60 | $1.02 |
| Average True Range (ATR) | 0.39 | 0.09 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 63.13 | 87.21 |
Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels. Geographically, the company has operations in the U.S., United Kingdom and Canada, of which United States derives maximum revenue.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.